Molex Acquires Vectura Group to Boost Inhalation Drug Delivery Expertise

Molex, a prominent American electronics company, is poised to significantly enhance its healthcare capabilities with the acquisition of Vectura Group Limited, a leader in inhalation drug delivery. This acquisition, expected to close by the end of 2024, will integrate Vectura’s expertise in inhalation therapies with Phillips Medisize, a Molex subsidiary known for designing and manufacturing healthcare products. The combined strengths of Vectura and Phillips Medisize are set to provide innovative solutions for treating respiratory conditions, benefiting both pharmaceutical clients and patients.

Vectura’s deep knowledge in inhaler devices, generic formulations, and nebulizer technology will complement Phillips Medisize’s advanced manufacturing and engineering capabilities. This strategic acquisition aligns with Molex’s ongoing efforts to expand its healthcare portfolio, which began with the acquisition of Phillips Medisize in 2016. Together, they will offer pharmaceutical companies a more comprehensive suite of drug-device combinations tailored to inhalation therapies.

With over 6,000 employees across 29 global locations, Phillips Medisize is already a major player in healthcare manufacturing, and this merger with Vectura will further drive innovation in treating chronic and acute respiratory conditions. By combining Vectura’s formulation and device development expertise with Phillips Medisize’s robust production capabilities, Molex is set to lead in the creation of advanced medical products aimed at improving health outcomes worldwide.

This acquisition represents a significant milestone for Molex in the medical device industry, enhancing its role in delivering cutting-edge healthcare solutions that address critical patient needs.